Hervé Ghesquières

Université Claude Bernard Lyon 1 — France

Medicine · Health Sciences

57h-index11.0kcitations527works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(356), Chronic Lymphocytic Leukemia Research(125), CNS Lymphoma Diagnosis and Treatment(124), CAR-T cell therapy research(93), Viral-associated cancers and disorders(70)

Publications525 total

The association between sarcoidosis and lymphoma: a retrospective and multicentre study of 46 patients.
PubMed·2025Open Access
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
Future Oncology·2025Open Access
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Journal of Clinical Oncology·2025Open Access
CO7 Addressing the Inherent Challenges of the French National Claims Database (SNDS) Through Algorithms to Identify Patients With Diffuse Large B-cell Lymphoma (DLBCL) and Their Chemotherapy Treatments
Value in Health·2025
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial
Annals of Oncology·2025· 1 cited
Impact of the ONCORAL multidisciplinary city-hospital follow-up on older patients with cancer treated with oral anticancer drugs
Supportive Care in Cancer·2025
Autologous, allogeneic haemopoietic stem cell transplantation and CART cell therapy for tranformed Waldenström's macroglobulinemia to high grade non-Hodgkin lymphoma. real world outcomes report from the lymphoma working party of the european society for blood and marrow transplantation (LWP EBMT)
Blood·2025Open Access
CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party
Blood·2025Open Access
Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation
Blood·2025Open Access
Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study.
Blood·2025Open Access
Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)
Blood·2025
Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries
Blood·2025
An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
Blood·2025Open Access
VACARME : Analysis of humoral protection at baseline and after vaccination in patients with refractory/relapsed lymphoma and myeloma treated with CD19 and BCMA CAR T-cells.
Blood·2025Open Access
Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003
Blood·2025Open Access
PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course
Blood·2025
Safety and efficacy of CD3xCD20 bispecific antibody for the treatment of primary and secondary central nervous system lymphoma patients: A multicentric retrospective study
Blood·2025Open Access
Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups
Blood·2025
Treatment options, responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa, a prospective multicentric lysa cohort
Blood·2025Open Access
Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL
Blood·2025Open Access
page 1 of 27Next →

Frequent Co-authors

Gilles Salles(18), Corinne Haïoun(14), Hervé Tilly(13), Olivier Casasnovas(13), Bertrand Coiffier(12), Thomas M. Habermann(10), Franck Morschhauser(10), Rémy Gressin(9), Khê Hoang‐Xuan(9), Emmanuel Gyan(9), Thierry Jo Molina(8), Emmanuelle Nicolas‐Virelizier(8), Brian K. Link(8), Carole Soussain(8), Sylvain Choquet(8), Caroline Houillier(8), Catherine Thiéblemont(7), Carrie A. Thompson(7), James R. Cerhan(7), Roch Houot(7)